Investor Relations | ImpediMed

Investor Relations

The Global Leader in Bioimpedance Spectroscopy Technology

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedence spectroscopy (BIS) technology to generate powerful data to maximise patient health.

Growth through SOZO SaaS Subscription-based Model

ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.

SOZO® Business Performance

Q2 FY’21

$1.9m

SOZO REVENUE
+58%
YOY^

$7.8m

ARRi
+86%
YOY

$14.8m

CRPii
+54%
YOY

28,000+

PATIENT TESTS
+33%
YOY

90%+

SaaS GROSS MARGINS

1%

CHURN RATE

^ YOY denotes Year-over-Year change in metric.
i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCViii that are yet to be reported as recognised revenue.
iii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.

All FY’21 revenue and cash flow numbers are unaudited.
ARR, CRP and TCV are unaudited, non-AASB financial metrics that do not represent revenue in accordance with Australian Accounting Standards. The values shown for total ARR and CRP across all lines of business, including the Core Business and Clinical Business.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Market Performance

AUD $138.08M

Market capitalisation

Investor Video Call Q2'21

YUHDops3yVQ

Investor Presentation Q2’21

YUHDops3yVQ

Annual Report 2020

Latest ASX Announcements

Analyst coverage

ImpediMed has market-leading coverage with the following entities:

Canaccord Genuity Morgans Wilsons

Share register

ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.

Share register agent

To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:

linkmarketservices.com.au

Ph: 1300-554-474
Fax: +61-2-9287-0303

Locked Bag A14
Sydney South
NSW 1235, Australia

Entitlement offer

Entitlement Offer Options

For every 1 New Share issued under the Company’s Accelerated Entitlement Offer, Eligible Shareholders were issued 1 free New Option, exercisable at a price of $0.0375 (3.75 cents) each.

The New Options are exercisable in whole or part on 30 June 2020, 30 September 2020, 31 December 2020, and 31 March 2021 (the date of their expiry) at a price of $0.0375 (3.75 cents) each, but not thereafter. New Options not exercised by 5pm (Sydney time) on 31 March 2021 will lapse.

Each New Option entitles the holder to subscribe for one Share. Any Shares issues as a result of exercising a New Option will be issued on the same terms and rank in all respects with existing Shares.

Each eligible Securityholder of New Options was provided a holding statement by the Share Registry that set out the number of New Options allotted to them. The notice also advised holders of their Security Holder Reference Number, the exercise price of the Options, and the date of issue of the New Options and the New Option Exercise Dates.

Exercising New Options

When exercising New Options, a New Option holder must give the Company or the Share Registry a Notice of Exercise of Options form, together with payment of the exercise monies payable to the Company in connection with the Options being exercised on or prior to the relevant New Option Exercise Date.

Notice of Exercise of Options form

If a New Option holder exercises less than the total number of its New Options, the Company must cancel the holding statement and issue the New Option holder a new holding statement for the remaining number of New Options held by the New Option holder.

The Company shall within five Business Days after the relevant New Option Exercise Date, subject to receipt of a Notice of Exercise of Option Form and cleared funds, issue Shares in respect of the New Options exercised and dispatch a holding statement to the holder. An application for official quotation of the Shares allotted and issued as a result of the exercise of the New Options will be made within ten Business Days after the date of issue of the Shares.

Refer to Section 9.2 of the Prospectus for the full terms and conditions of the New Options.

Shareholder services

Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:

InvestorRelations@impedimed.com

ImpediMed maintains an active communications program with investors and the market.

Contact

Investor Relations Contact:

Mike Bassett, Senior Vice President, Corporate and Strategic Development, ImpediMed

+61 4 0743 1432

mbassett@impedimed.com

InvestorRelations@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

+61 3 9866 4722

kwilliamson@we-worldwide.com